-
1Academic Journal
Συγγραφείς: Gurevich L.E., Ilovayskaya I.A., Lugovskaya A.Y., Markarova E.V., Kogoniya L.M., Setdikova G.R., Tyurina V.M., Yakovenko I.P.
Συνεισφορές: 1
Πηγή: Almanac of Clinical Medicine; Vol 53, No 4 (2025); 169-179 ; Альманах клинической медицины; Vol 53, No 4 (2025); 169-179 ; 2587-9294 ; 2072-0505
Θεματικοί όροι: Oct4, neuroendocrine tumors, pheochromocytoma, paraganglioma, functional type, malignant potential, нейроэндокринные опухоли, феохромоцитома, параганглиома, функциональный тип, злокачественный потенциал
Περιγραφή αρχείου: application/pdf
Relation: https://almclinmed.ru/jour/article/view/17541/1753; https://almclinmed.ru/jour/article/view/17541/1754; https://almclinmed.ru/jour/article/downloadSuppFile/17541/160715; https://almclinmed.ru/jour/article/downloadSuppFile/17541/160716; https://almclinmed.ru/jour/article/downloadSuppFile/17541/160717; https://almclinmed.ru/jour/article/downloadSuppFile/17541/160718; https://almclinmed.ru/jour/article/downloadSuppFile/17541/160719; https://almclinmed.ru/jour/article/downloadSuppFile/17541/160720; https://almclinmed.ru/jour/article/downloadSuppFile/17541/160721; https://almclinmed.ru/jour/article/downloadSuppFile/17541/160722; https://almclinmed.ru/jour/article/downloadSuppFile/17541/160723; https://almclinmed.ru/jour/article/downloadSuppFile/17541/160724; https://almclinmed.ru/jour/article/view/17541
-
2Academic Journal
Συγγραφείς: Ilovayskaya I.A., Lugovskaya A.Y., Glazkov A.A., Britvin T.A., Gurevich L.E., Shikina V.E.
Συνεισφορές: 0
Πηγή: Almanac of Clinical Medicine; Vol 53, No 2 (2025); 71-82 ; Альманах клинической медицины; Vol 53, No 2 (2025); 71-82 ; 2587-9294 ; 2072-0505
Θεματικοί όροι: adrenal incidentaloma, pheochromocytoma, adrenocortical carcinoma, hormonally non-functioning adrenal adenomas, arterial hypertension, computed tomography, phenotype, differential diagnostics, инциденталома надпочечника, феохромоцитома, адренокортикальный рак, гормонально-неактивные опухоли надпочечника, артериальная гипертензия, компьютерная томография, фенотип, дифференциальная диагностика
Περιγραφή αρχείου: application/pdf
Relation: https://almclinmed.ru/jour/article/view/17415/1738; https://almclinmed.ru/jour/article/downloadSuppFile/17415/160385; https://almclinmed.ru/jour/article/downloadSuppFile/17415/160552; https://almclinmed.ru/jour/article/downloadSuppFile/17415/160553; https://almclinmed.ru/jour/article/downloadSuppFile/17415/160554; https://almclinmed.ru/jour/article/downloadSuppFile/17415/160555; https://almclinmed.ru/jour/article/downloadSuppFile/17415/160556; https://almclinmed.ru/jour/article/downloadSuppFile/17415/160557; https://almclinmed.ru/jour/article/downloadSuppFile/17415/160558; https://almclinmed.ru/jour/article/downloadSuppFile/17415/160559; https://almclinmed.ru/jour/article/downloadSuppFile/17415/160560; https://almclinmed.ru/jour/article/downloadSuppFile/17415/160561; https://almclinmed.ru/jour/article/downloadSuppFile/17415/160562; https://almclinmed.ru/jour/article/downloadSuppFile/17415/160563; https://almclinmed.ru/jour/article/downloadSuppFile/17415/160564; https://almclinmed.ru/jour/article/downloadSuppFile/17415/160565; https://almclinmed.ru/jour/article/downloadSuppFile/17415/160566; https://almclinmed.ru/jour/article/downloadSuppFile/17415/160567; https://almclinmed.ru/jour/article/downloadSuppFile/17415/160568; https://almclinmed.ru/jour/article/downloadSuppFile/17415/160569; https://almclinmed.ru/jour/article/view/17415
-
3Academic Journal
Συγγραφείς: Sen, S., Bhattacharjee, S., Ghosh, I., Thakkar, D.B., Hajra, S., Dasgupta, P.
Πηγή: Mìžnarodnij Endokrinologìčnij Žurnal, Vol 16, Iss 5, Pp 432-437 (2020)
Міжнародний ендокринологічний журнал-Mìžnarodnij endokrinologìčnij žurnal; Том 16, № 5 (2020); 432-437
Международный эндокринологический журнал-Mìžnarodnij endokrinologìčnij žurnal; Том 16, № 5 (2020); 432-437
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY; Том 16, № 5 (2020); 432-437Θεματικοί όροι: феохромоцитома, нормотензивная феохромоцитома, инциденталома надпочечников, «молчаливая» феохромоцитома, бессимптомная феохромоцитома, 03 medical and health sciences, 0302 clinical medicine, normotensive incidental pheochromocytoma, pheochromocytoma, adrenal incidentaloma, silent pheochromocytoma, asymptomatic pheochromocytoma, нормотензивна феохромоцитома, інциденталома надниркової залози, «мовчазна» феохромоцитома, безсимптомна феохромоцитома, RC648-665, Diseases of the endocrine glands. Clinical endocrinology, 3. Good health
Περιγραφή αρχείου: application/pdf
-
4Academic Journal
Συγγραφείς: A. P. Chuprina, A. N. Bobin, M. S. Pecherskaya, R. E. Segedin, А. П. Чуприна, А. Н. Бобин, М. С. Печерская, Р. Е. Сегедин
Πηγή: Cancer Urology; Том 19, № 4 (2023); 114-118 ; Онкоурология; Том 19, № 4 (2023); 114-118 ; 1996-1812 ; 1726-9776
Θεματικοί όροι: адреналэктомия, pheochromocytoma, adenomatoid tumor, mesothelial tissue tumor, adrenal gland incidentaloma, adrenalectomy, феохромоцитома, аденоматоидная опухоль, опухоль из мезотелиальной ткани, инциденталома надпочечников
Περιγραφή αρχείου: application/pdf
Relation: https://oncourology.abvpress.ru/oncur/article/view/1600/1498; WHO Classification of Tumours. Available at: https://tumourclassification.iarc.who.int/chaptercontent/38/71.; Lehman K.A., Zynger D.L. Adrenal gland & paraganglia. Available at: https://www.pathologyoutlines.com/topic/adrenaladenomatoid.html.; Lack E.E. Tumors of the adrenal gland. In: Diagnostic Histopathology of Tumors. Ed.: C. Fletcher. 3rd edn. Churchill Livingstone Elsevier, 2007. Pp. 1099–122.; Delellis R.A., Mangray S. The adrenal glands. In: Sternberg’s Diagnostic Surgical Pathology. Eds.: S.E. Mills, D. Carter, J. Greenson. 5th ed. Lippincott Williams and Wilkins, 2009. Pp. 545–567.; Adem C., Schneider M., Hoang C. Pathologic quiz case: an unusual umbilical mass. Arch Pathol Lab Med 2003;127(7):303–4. DOI:10.5858/2003-127-e303-PQCAUU; Kaplan M.A., Tazelaar H.D., Hayashi T. et al. Adenomatoid tumor of the pleura. Am J Surg Pathol 1996;20(10):1219–23. DOI:10.1097/00000478-199610000-00007; Hanrahan J.B. A combined papillary mesothelioma and adenomatoid tumor of the omentum: report of the case. Cancer 1971;27: 109–14.; Isotalo P.A., Nascimento A.G., Trastek V.F. et al. Extragenital adenomatoid tumor of a mediastinal lymph node. Mayo Clin Proc 2003;78(3):350–4. DOI:10.4065/78.3.350; Benisch B.M. A retroperitoneal mesonephric cystadenoma with features of the adenomatoid tumor of the genital tract. J Urol 1973;110(1):44–6. DOI:10.1016/s0022-5347(17)60110-1; Craig J.R., Hart W.R. Extargenital adenomatoid tumor: evidence for mesothelial theory of origin. Cancer 1979;43(5):1678–82. DOI:10.1002/1097-0142(197905)43:53.0.co;2-n; Evans C.P., Vaccaro J.A., Storrs B.G. Suprarenal occurrence of an adenomatoid tumor. J Urol 1988;139(2):348–9. DOI:10.1016/s0022-5347(17)42410-4; Hoffmann M., Yedibela S., Hohenberger W. et al. Adenomatoid tumor of the adrenal gland. Int J Surg 2008;6(6):485–7. DOI:10.1016/j.ijsu.2006.06.025; Raaf H.N., Grant L.D., Santoscoy C. et al. Adenomatoid tumor of the adrenal gland: a report of four new cases and a review of the literature. Mod Pathol 1996;9(11):1046–51.; https://www.nordiqc.org/epitope.php?id=77; http://e-immunohistochemistry.info/web/Calretinin.htm; http://www.microtesty.ru/catalog/calretinin_polyclonal_rabbit; https://www.pathologyoutlines.com/topic/stainsD240.html; Zhao M., Li C., Zheng J. et al. Cystic lymphangioma-like adenomatoid tumor of the adrenal gland: report of a rare case and review of the literature. Int J Clin Exp Pathol 2013;6(5):943–50.; Golden A., Ash J.E. Adenomatoid tumors of the genital tract. Am J Pathol 1945;21(1):63–79.; Mantero F., Terzolo M., Arnaldi G. et al. A survey on adrenal incidentaloma in Itali. Study Group on Adrenal Tumors of the Italian Society of Endocrinology. J Clin Endocrinol Metab 2000;85(2): 637–44. DOI:10.1210/jcem.85.2.6372; Evans C.P., Vaccaro J.A., Storrs B.G., Christ P.J. Suprarenal occurrence of an adenomatoid tumor. J Urol 1988;139(2):348–9. DOI:10.1016/s0022-5347(17)42410-4; https://oncourology.abvpress.ru/oncur/article/view/1600
-
5Academic Journal
Συγγραφείς: R. V. Milutis, E. A. Kovaleva, N. V. Matinyan, A. S. Temnyy, A. P. Kazantsev, V. O. Khoroshilova, I. A. Letyagin, Р. В. Милутис, Е. А. Ковалева, Н. В. Матинян, А. С. Тёмный, А. П. Казанцев, В. О. Хорошилова, И. А. Летягин
Συνεισφορές: The study was performed without external funding, Исследование проведено без спонсорской поддержки
Πηγή: Russian Journal of Pediatric Hematology and Oncology; Том 11, № 3 (2024); 71-77 ; Российский журнал детской гематологии и онкологии (РЖДГиО); Том 11, № 3 (2024); 71-77 ; 2413-5496 ; 2311-1267
Θεματικοί όροι: эпидуральная анальгезия, pheochromocytoma, anesthesiology-resuscitation, extended perioperative monitoring, epidural analgesia, феохромоцитома, анестезиология-реанимация, расширенный периоперационный мониторинг
Περιγραφή αρχείου: application/pdf
Relation: https://journal.nodgo.org/jour/article/view/1074/935; Мельниченко Г.А., Трошина Е.А., Бельцевич Д.Г., Кузнецов Н.С., Юкина М.Ю. Клинические рекомендации Российской ассоциации эндокринологов по диагностике и лечению феохромоцитомы/параганглиомы. Эндокринная хирургия. 2015;9(3):15–33. doi:10.14341/serg2015315-33.; Barontini M., Levin G., Sanso G. Characteristics of pheochromocytoma in a 4to 20-year-old population. Ann N Y Acad Sci. 2006;1073:30–7. doi:10.1196/annals.1353.003.; Jochmanova I., Abcede A.M.T., Guerrero R.J.S., Malong C.L.P., Wesley R., Huynh T., Gonzales M.K., Wolf K.I., Jha A., Knue M., Prodanov T., Nilubol N., Mercado-Asis L.B., Stratakis C.A., Pacak K. Clinical characteristics and outcomes of SDHB-related pheochromocytoma and paraganglioma in children and adolescents. J Cancer Res Clin Oncol. 2020;146(4):1051–63. doi:10.1007/s00432-020-03138-5.; Bausch B., Wellner U., Bausch D., Schiavi F., Barontini M., Sanso G., Walz M.K., Peczkowska M., Weryha G., Dall’igna P., Cecchetto G., Bisogno G., Moeller L.C., Bockenhauer D., Patocs A., Rácz K., Zabolotnyi D., Yaremchuk S., Dzivite-Krisane I., Castinetti F., Taieb D., Malinoc A., von Dobschuetz E., Roessler J., Schmid K.W., Opocher G., Eng C., Neumann H.P. Long-term prognosis of patients with pediatric pheochromocytoma. Endocr Relat Cancer. 2013;21(1):17–25. doi:10.1530/ERC-13-0415.; Ludwig A.D., Feig D.I., Brandt M.L., Hicks M.J., Fitch M.E., Cass D.L. Recent advances in the diagnosis and treatment of pheochromocytoma in children. Am J Surg. 2007;194(6):792–6; discussion 796–7. doi:10.1016/j.amjsurg.2007.08.028.; Havekes B., Romijn J.A., Eisenhofer G., Adams K., Pacak K. Update on pediatric pheochromocytoma. Pediatr Nephrol. 2009;24(5):943–50. doi:10.1007/s00467-008-0888-9.; Londe S. Causes of hypertension in the young. Pediatr Clin North Am. 1978;25(1):55–65. doi:10.1016/S0031-3955(16)33532-5.; Pacak K., Linehan W.M., Eisenhofer G., Walther M.M., Goldstein D.S. Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma. Ann Intern Med. 2001;134(4):315–29. doi:10.7326/0003-4819-134-4-200102200-00016.; Deutschbein T., Unger N., Jaeger A., Broecker-Preuss M., Mann K., Petersenn S. Influence of various confounding variables and storage conditions on metanephrine and normetanephrine levels in plasma. Clin Endocrinol. 2010;73(2):153–60. doi:10.1111/j.1365-2265.2009.03761.x.; Hoy L.J., Emery M., Wedzicha J.A., Davison A.G., Chew S.L., Monson J.P. Obstructive sleep apnea presenting as pseudopheochromocytoma: a case report. J Clin Endocrinol Metab. 2004;89(5):2033–8. doi:10.1210/jc.2003-031348.; Challis B.G., Casey R.T., Simpson H.L., Gurnell M. Is there an optimal reoperative management strategy phaeochromocytoma/ paraganglioma? Clin Endocrinol. (Oxf) 2017;86(2):163–7. doi:10.1111/cen.13252.; Fishbein L., Orlowski R., Cohen D. Pheochromocytoma/ paraganglioma: review of perioperative management of blood pressure and update on genetic mutations associated with pheochromocytoma. J Clin Hypertens (Greenwich). 2013;15(6):428–34. doi:10.1111/jch.12084.; Prys-Roberts C., Farndon J.R. Efficacy and safety of doxazosin for perioperative management of patients with pheochromocytoma. World J Surg. 2002;26(8):1037–42. doi:10.1007/s00268-002-6667-z.; Kocak S., Aydintug S., Canakci N. Alpha blockade in preoperative preparation of patients with pheochromocytomas. Int Surg. 2002;87(3):191–4. PMID: 12403097.; Hack H.A. The perioperative management of children with phaeochromocytoma. Paediatr Anaesth. 2000;10(5):463–76. doi:10.1046/j.1460-9592.2000.00504.x.; https://journal.nodgo.org/jour/article/view/1074
-
6Academic Journal
Συγγραφείς: Аlimukhamedova, H.А., Khalimova, Z.Yu.
Πηγή: Mìžnarodnij Endokrinologìčnij Žurnal, Vol 11, Iss 6.70, Pp 57-61 (2015)
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY; № 6.70 (2015); 57-61
Международный эндокринологический журнал-Mìžnarodnij endokrinologìčnij žurnal; № 6.70 (2015); 57-61
Міжнародний ендокринологічний журнал-Mìžnarodnij endokrinologìčnij žurnal; № 6.70 (2015); 57-61Θεματικοί όροι: aldosteronoma, утворення надниркових залоз, комп'ютерна томографія, альдостерома, кортикостерома, феохромоцитома, corticosteroma, computed tomography, RC648-665, образования надпочечников, компьютерная томография, pheochromocytoma, 7. Clean energy, Diseases of the endocrine glands. Clinical endocrinology, 3. Good health, 03 medical and health sciences, 0302 clinical medicine, 13. Climate action, adrenal masses
Περιγραφή αρχείου: application/pdf
Σύνδεσμος πρόσβασης: http://iej.zaslavsky.com.ua/article/download/72642/144139
https://doaj.org/article/c2ced61ebfd947a0b6f0f7035a8b7735
http://iej.zaslavsky.com.ua/article/download/72642/144139
http://iej.zaslavsky.com.ua/article/view/72642
https://core.ac.uk/display/87762834
http://iej.zaslavsky.com.ua/article/view/72642 -
7Academic Journal
Πηγή: Госпитальная медицина: наука и практика. 4:11-14
Θεματικοί όροι: феохромоцитома надпочечника, артериальная гипертензия, метанефрины, 3. Good health
-
8Book
Συγγραφείς: Рибаков, С. Й., Шідловський, В. О.
Θεματικοί όροι: феохромоцитома, парагангліома, патологія хромафінної тканини, пухлини хромафінної тканини, феохромоцитома в дітей, феохромоцитома у вагітних жінок, феохромоцитома сечового міхура, синдром псевдофеохромоцитоми, феохромоцитома в осіб похилого віку
Περιγραφή αρχείου: application/pdf
Relation: Рибаков С. Й. Феохромоцитома : монографія / С. Й. Рибаков, В. О. Шідловський. Тернопіль : ТНМУ, 2022. 296 с.; https://repository.tdmu.edu.ua//handle/123456789/17881
Διαθεσιμότητα: https://repository.tdmu.edu.ua//handle/123456789/17881
-
9Academic Journal
Συγγραφείς: A. V. Hajrieva, N. V. Tarbaeva, N. N. Volevodz, L. D. Kovalevich, K. A. Komshilova, N. M. Platonova, N. V. Latkina, N. S. Kuznecov, V. Yu. Kalashnikov, N. G. Mokrysheva, А. В. Хайриева, Н. В. Тарбаева, Н. Н. Волеводз, Л. Д. Ковалевич, К. А. Комшилова, Н. М. Платонова, Н. В. Латкина, Н. С. Кузнецов, В. Ю. Калашников, Н. Г. Мокрышева
Πηγή: Diagnostic radiology and radiotherapy; Том 14, № 2 (2023); 93-101 ; Лучевая диагностика и терапия; Том 14, № 2 (2023); 93-101 ; 2079-5343
Θεματικοί όροι: гемангиобластома, pheochromocytoma, hemangioblastoma, феохромоцитома
Περιγραφή αρχείου: application/pdf
Relation: https://radiag.bmoc-spb.ru/jour/article/view/882/601; Maher E.R., Iselius L., Yates J.R. et al. Von Hippel–Lindau disease: a genetic study // J. Med. Genet. 1991. No. 28. Р. 443–447.; Latif F., Tory K., Gnarra J. et al. Identification of the von Hippel–Lindau disease tumor suppressor gene // Science. 1993. No. 260. Р. 1317–1320.; Chen F., Kishida T., Yao M. et al. Germline mutations in the von Hippel–Lindau disease tumor suppressor gene: correlation with phenotype // Hum. Mutat. 1995. No. 5. Р. 66–75.; DeLellis R.A., Lloyd R.V., Heitz P.U. et al. World Health Organization classification of tumors: Pathology and genetics of tumours of endocrine organs. Lyon: IARC Press, 2004.; Gross D., Avishai N., Meiner V. et al. Familial pheochromocytoma associated with a novel mutation in the von Hippel–Lindau gene // JCEM. 1996. No. 81. Р. 147–149.; Wanebo J.E., Lonser R.R., Glenn G.M. et al. The natural history of hemangioblastomas of the central nervous system in patients with von Hippel-Lindau disease // J. Neurosurg. 2003. No. 98. Р. 82–94.
-
10Academic Journal
Συγγραφείς: O. M. Symonov, V. A. Kondratiuk, O. M. Gulko, M. Yu. Bolgov, A. E. Kovalenko, A. V. Skums
Πηγή: Клінічна хірургія, Vol 86, Iss 4, Pp 16-20 (2019)
Θεματικοί όροι: 03 medical and health sciences, 0302 clinical medicine, RD1-811, Surgery, феохромоцитома, лапароскопія, рентгенендоваскулярна селективна електрокоагуляційна оклюзія, адреналектомія, гемодинамічна нестабільність
-
11Academic Journal
Συγγραφείς: D. D. Omelchuk, M. V. Degtyarev, P. O. Rumyantsev, Д. Д. Омельчук, М. В. Дегтярев, П. О. Румянцев
Πηγή: Medical Herald of the South of Russia; Том 13, № 1 (2022); 52-64 ; Медицинский вестник Юга России; Том 13, № 1 (2022); 52-64 ; 2618-7876 ; 2219-8075 ; 10.21886/2219-8075-2022-13-1
Θεματικοί όροι: ПЭТ/КТ, molecular visualization, adrenal tumors, pheochromocytoma, SPECT, review, молекулярная визуализация, опухоли надпочечников, феохромоцитома, альдостерома, ОФЭКТ/КТ
Περιγραφή αρχείου: application/pdf
Relation: https://www.medicalherald.ru/jour/article/view/1498/869; https://www.medicalherald.ru/jour/article/downloadSuppFile/1498/564; Reincke M. Subclinical Cushing’s syndrome. Endocrinol Metab Clin North Am. 2000;29(1):43-56. DOI:10.1016/s0889-8529(05)70115-8; Agrawal A, Rangarajan V, Shah S, Puranik A, Purandare N. MIBG (metaiodobenzylguanidine) theranostics in pediatric and adult malignancies. Br J Radiol. 2018;91(1091):20180103. DOI:10.1259/bjr.20180103; Vallabhajosula S, Nikolopoulou A. Radioiodinated metaiodobenzylguanidine (MIBG): radiochemistry, biology, and pharmacology. Semin Nucl Med. 2011;41(5):324-33. DOI:10.1053/j.semnuclmed.2011.05.003; ECopy, Inc. - Food and Drug Administration [Internet]. [cited 2021Dec18]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022290s000_ClinPharmR.pdf; Green M, Lowe J, Kadirvel M, McMahon A, Westwood N, et al. Radiosynthesis of no-carrier-added meta-[124I] iodobenzylguanidine for PET imaging of metastatic neuroblastoma. J Radioanal Nucl Chem. 2017;311(1):727732. DOI:10.1007/s10967-016-5073-1; Hartung-Knemeyer V, Rosenbaum-Krumme S, Buchbender C, Pöppel T, Brandau W, et al. Malignant pheochromocytoma imaging with [124I]mIBG PET/MR. J Clin Endocrinol Metab. 2012;97(11):3833-4. DOI:10.1210/jc.2012-1958; Cistaro A, Quartuccio N, Caobelli F, Piccardo A, Paratore R, et al. 124I-MIBG: a new promising positron-emitting radiopharmaceutical for the evaluation of neuroblastoma. Nucl Med Rev Cent East Eur. 2015;18(2):102-6. DOI:10.5603/NMR.2015.0024; Francis I.R., Mayo-Smith W.W. Adrenal Imaging. In: Hodler J., Kubik-Huch R., von Schulthess G. (eds) Diseases of the Abdomen and Pelvis 2018-2021. IDKD Springer Series. Springer, Cham; 2018. DOI:10.1007/978-3-319-75019-4_9; Mariani-Costantini R, editor. Paraganglioma: A Multidisciplinary Approach [Internet]. Brisbane (AU): Codon Publications; 2019. PMID: 31294937.; Gimenez-Roqueplo AP, Caumont-Prim A, Houzard C, Hignette C, Hernigou A, et al. Imaging work-up for screening of paraganglioma and pheochromocytoma in SDHx mutation carriers: a multicenter prospective study from the PGL.EVA Investigators. J Clin Endocrinol Metab. 2013;98(1):E162-73. DOI:10.1210/jc.2012-2975; Naji M, Zhao C, Welsh SJ, Meades R, Win Z, et al. 68Ga-DOTATATE PET vs. 123I-MIBG in identifying malignant neural crest tumours. Mol Imaging Biol. 2011;13(4):769-75. DOI:10.1007/s11307-010-0396-8; Kroiss A, Shulkin BL, Uprimny C, Frech A, Gasser RW, et al. (68)Ga-DOTATOC PET/CT provides accurate tumour extent in patients with extraadrenal paraganglioma compared to (123)I-MIBG SPECT/CT. Eur J Nucl Med Mol Imaging. 2015;42(1):33-41. DOI:10.1007/s00259-014-2892-6; van Hulsteijn LT, Niemeijer ND, Dekkers OM, Corssmit EP. (131)I-MIBG therapy for malignant paraganglioma and phaeochromocytoma: systematic review and meta-analysis. Clin Endocrinol (Oxf). 2014;80(4):487-501. DOI:10.1111/cen.12341; Rao D, van Berkel A, Piscaer I, Young WF, Gruber L, et al. Impact of 123 I-MIBG scintigraphy on clinical decision making in pheochromocytoma and paraganglioma. J Clin Endocrinol Metab. 2019:jc.2018-02355. DOI:10.1210/jc.2018-02355. Epub ahead of print; Vyakaranam AR, Crona J, Norlén O, Granberg D, GarskeRomán U, et al. Favorable Outcome in Patients with Pheochromocytoma and Paraganglioma Treated with 177Lu-DOTATATE. Cancers (Basel). 2019;11(7):909. DOI:10.3390/cancers11070909; Granberg D, Juhlin CC, Falhammar H. Metastatic Pheochromocytomas and Abdominal Paragangliomas. J Clin Endocrinol Metab. 2021;106(5):e1937-e1952. DOI:10.1210/clinem/dgaa982; Loh KC, Fitzgerald PA, Matthay KK, Yeo PP, Price DC. Th e treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (131I-MIBG): a comprehensive review of 116 reported patients. J Endocrinol Invest. 1997;20(11):648-58. DOI:10.1007/BF03348026; Gonias S, Goldsby R, Matthay KK, Hawkins R, Price D, et al. Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma. J Clin Oncol. 2009;27(25):4162-8. DOI:10.1200/JCO.2008.21.3496; Pryma DA, Chin BB, Noto RB, Dillon JS, Perkins S, et al. Efficacy and Safety of High-Specifi c-Activity 131I-MIBG Th erapy in Patients with Advanced Pheochromocytoma or Paraganglioma. J Nucl Med. 2019;60(5):623-630. DOI:10.2967/jnumed.118.217463; Barrett JA, Joyal JL, Hillier SM, Maresca KP, Femia FJ, et al. Comparison of high-specifi c-activity ultratrace 123/131I-MIBG and carrier-added 123/131I-MIBG on efficacy, pharmacokinetics, and tissue distribution. Cancer Biother Radiopharm. 2010;25(3):299-308. DOI:10.1089/cbr.2009.0695; Nastos K, Cheung VTF, Toumpanakis C, Navalkissoor S, Quigley AM, et al. Peptide Receptor Radionuclide Treatment and (131)I-MIBG in the management of patients with metastatic/progressive phaeochromocytomas and paragangliomas. J Surg Oncol. 2017;115(4):425-434. DOI:10.1002/jso.24553; Ohshima Y, Sudo H, Watanabe S, Nagatsu K, Tsuji AB, et al. Antitumor eff ects of radionuclide treatment using α-emitting meta-211At-astato-benzylguanidine in a PC12 pheochromocytoma model. Eur J Nucl Med Mol Imaging. 2018;45(6):999-1010. DOI:10.1007/s00259-017-3919-6; Chauhan A, El-Khouli R, Waits T, Agrawal R, Siddiqui F, et al. Post FDA approval analysis of 200 gallium-68 DOTATATE imaging: A retrospective analysis in neuroendocrine tumor patients. Oncotarget. 2020;11(32):3061-3068. DOI:10.18632/oncotarget.27695; Srirajaskanthan R, Kayani I, Quigley AM, Soh J, Caplin ME, Bomanji J. Th e role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal fi ndings on 111In-DTPA-octreotide scintigraphy. J Nucl Med. 2010;51(6):875-82. DOI:10.2967/jnumed.109.066134; Han S, Suh CH, Woo S, Kim YJ, Lee JJ. Performance of 68Ga-DOTA-Conjugated Somatostatin Receptor-Targeting Peptide PET in Detection of Pheochromocytoma and Paraganglioma: A Systematic Review and Metaanalysis. J Nucl Med. 2019;60(3):369-376. DOI:10.2967/jnumed.118.211706; Wild D, Bomanji JB, Benkert P, Maecke H, Ell PJ, Reubi JC, Caplin ME. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors. J Nucl Med. 2013;54(3):364-72. DOI:10.2967/jnumed.112.111724; Gild ML, Naik N, Hoang J, Hsiao E, McGrath RT, et al. Role of DOTATATE-PET/CT in preoperative assessment of phaeochromocytoma and paragangliomas. Clin Endocrinol (Oxf). 2018;89(2):139-147. DOI:10.1111/cen.13737; Chang CA, Pattison DA, Tothill RW, Kong G, Akhurst TJ, et al. (68) Ga-DOTATATE and (18)F-FDG PET/CT in Paraganglioma and Pheochromocytoma: utility, patterns and heterogeneity. Cancer Imaging. 2016;16(1):22. DOI:10.1186/s40644-016-0084-2; Janssen I, Blanchet EM, Adams K, Chen CC, Millo CM, et al. Superiority of [68Ga]-DOTATATE PET/CT to Other Functional Imaging Modalities in the Localization of SDHB-Associated Metastatic Pheochromocytoma and Paraganglioma. Clin Cancer Res. 2015;21(17):3888-95. DOI:10.1158/1078-0432.CCR-14-2751; Janssen I, Chen CC, Millo CM, Ling A, Taieb D, et al. PET/CT comparing (68)Ga-DOTATATE and other radiopharmaceuticals and in comparison with CT/MRI for the localization of sporadic metastatic pheochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging. 2016;43(10):1784-91. DOI:10.1007/s00259016-3357-x; Janssen I, Chen CC, Taieb D, Patronas NJ, Millo CM, et al. 68GaDOTATATE PET/CT in the Localization of Head and Neck Paragangliomas Compared with Other Functional Imaging Modalities and CT/MRI. J Nucl Med. 2016;57(2):186-91. DOI:10.2967/jnumed.115.161018; Janssen I, Chen CC, Zhuang Z, Millo CM, Wolf KI, et al. Functional Imaging Signature of Patients Presenting with Polycythemia/Paraganglioma Syndromes. J Nucl Med. 2017;58(8):1236-1242. DOI:10.2967/jnumed.116.187690; Jha A, Ling A, Millo C, Gupta G, Viana B, et al. Superiority of 68Ga-DOTATATE over 18F-FDG and anatomic imaging in the detection of succinate dehydrogenase mutation (SDHx )-related pheochromocytoma and paraganglioma in the pediatric population. Eur J Nucl Med Mol Imaging. 2018;45(5):787-797. DOI:10.1007/s00259-017-3896-9; Jha A, de Luna K, Balili CA, Millo C, Paraiso CA, et al. Clinical, Diagnostic, and Treatment Characteristics of SDHA-Related Metastatic Pheochromocytoma and Paraganglioma. Front Oncol. 2019;9:53. DOI:10.3389/fonc.2019.00053; Jha A, Ling A, Millo C, Chen C, Gonzales M, et al. 2019b Diagnostic performance of PET/CT utilizing 68Ga-DOTATATE, 18F-FDG, 18F-DOPA, and 18F-FDA, and anatomic imaging in the detection of sporadic primary pheochromocytoma - A comparative prospective study. Journal of Nuclear Medicine. 2019:439.; Kroiss A, Putzer D, Frech A, Decristoforo C, Uprimny C, et al. A retrospective comparison between 68Ga-DOTA-TOC PET/ CT and 18F-DOPA PET/CT in patients with extra-adrenal paraganglioma. Eur J Nucl Med Mol Imaging. 2013;40(12):18008. DOI:10.1007/s00259-013-2548-y; Herrmann K, Czernin J, Wolin EM, Gupta P, Barrio M, et al. Impact of 68Ga-DOTATATE PET/CT on the management of neuroendocrine tumors: the referring physician’s perspective. J Nucl Med. 2015;56(1):70-5. DOI:10.2967/jnumed.114.148247; McGowan A, An JY, Tanakchi S, Maruf M, Muthigi A, et al. Multiple Recurrent Paraganglioma in a Pediatric Patient with Germline SDH-B Mutation. Urol Case Rep. 2017;13:107-109. DOI:10.1016/j.eucr.2017.03.017; Krebs S, Pandit-Taskar N, Reidy D, Beattie BJ, Lyashchenko SK, et al. Biodistribution and radiation dose estimates for 68GaDOTA-JR11 in patients with metastatic neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2019;46(3):677-685. DOI:10.1007/s00259-018-4193-y; Zhu W, Cheng Y, Wang X, Yao S, Bai C, et al. Head-to-Head Comparison of 68Ga-DOTA-JR11 and 68Ga-DOTATATE PET/CT in Patients with Metastatic, Well-Diff erentiated Neuroendocrine Tumors: A Prospective Study. J Nucl Med. 2020;61(6):897-903. DOI:10.2967/jnumed.119.235093; Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, et al. Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med. 2017;376(2):125-135. DOI:10.1056/NEJMoa1607427; Strosberg J, Wolin E, Chasen B, Kulke M, Bushnell D, et al. Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With 177LuDotatate in the Phase III NETTER-1 Trial. J Clin Oncol. 2018;36(25):2578-2584. DOI:10.1200/JCO.2018.78.5865; Brabander T, van der Zwan WA, Teunissen JJM, Kam BLR, Feelders RA, et al. Long-Term Efficacy, Survival, and Safety of [177Lu-DOTA0,Tyr3]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors. Clin Cancer Res. 2017;23(16):4617-4624. DOI:10.1158/1078-0432.CCR-16-2743; Yadav MP, Ballal S, Bal C. Concomitant 177Lu-DOTATATE and capecitabine therapy in malignant paragangliomas. EJNMMI Res. 2019;9(1):13. DOI:10.1186/s13550-019-0484-y; Kong G, Grozinsky-Glasberg S, Hofman MS, Callahan J, Meirovitz A, et al. Efficacy of Peptide Receptor Radionuclide Th erapy for Functional Metastatic Paraganglioma and Pheochromocytoma. J Clin Endocrinol Metab. 2017;102(9):3278-3287. DOI:10.1210/jc.2017-00816; Zandee WT, Feelders RA, Smit Duijzentkunst DA, Hofl and J, Metselaar RM, et al. Treatment of inoperable or metastatic paragangliomas and pheochromocytomas with peptide receptor radionuclide therapy using 177Lu-DOTATATE. Eur J Endocrinol. 2019;181(1):45-53. DOI:10.1530/EJE-18-0901; Satapathy S, Mittal BR, Bhansali A. ‘Peptide receptor radionuclide therapy in the management of advanced pheochromocytoma and paraganglioma: A systematic review and meta-analysis’. Clin Endocrinol (Oxf). 2019;91(6):718727. DOI:10.1111/cen.14106; Öksüz MÖ, Winter L, Pfannenberg C, Reischl G, Müssig K, et al. Peptide receptor radionuclide therapy of neuroendocrine tumors with (90)Y-DOTATOC: is treatment response predictable by pre-therapeutic uptake of (68)Ga-DOTATOC? Diagn Interv Imaging. 2014;95(3):289-300. DOI:10.1016/j.diii.2013.07.006; Lau J, Jacobson O, Niu G, Lin KS, Bénard F, Chen X. Bench to Bedside: Albumin Binders for Improved Cancer Radioligand Th erapies. Bioconjug Chem. 2019;30(3):487-502. DOI:10.1021/acs.bioconjchem.8b00919; Bandara N, Jacobson O, Mpoy C, Chen X, Rogers BE. Novel Structural Modifi cation Based on Evans Blue Dye to Improve Pharmacokinetics of a Somastostatin-Receptor-Based Th eranostic Agent. Bioconjug Chem. 2018;29(7):2448-2454. DOI:10.1021/acs.bioconjchem.8b00341; Wang H, Cheng Y, Zhang J, Zang J, Li H, et al. Response to Single Low-dose 177Lu-DOTA-EB-TATE Treatment in Patients with Advanced Neuroendocrine Neoplasm: A Prospective Pilot Study. Th eranostics. 2018;8(12):3308-3316. DOI:10.7150/thno.25919; van Berkel A, Rao JU, Kusters B, Demir T, Visser E, et al. Correlation between in vivo 18F-FDG PET and immunohistochemical markers of glucose uptake and metabolism in pheochromocytoma and paraganglioma. J Nucl Med. 2014;55(8):1253-9. DOI:10.2967/jnumed.114.137034; Maurea S, Mainolfi C, Bazzicalupo L, Panico MR, Imparato C, et al. Imaging of adrenal tumors using FDG PET: comparison of benign and malignant lesions. AJR Am J Roentgenol. 1999;173(1):25-9. DOI:10.2214/ajr.173.1.10397094; Kim SJ, Lee SW, Pak K, Kim IJ, Kim K. Diagnostic accuracy of 18F-FDG PET or PET/CT for the characterization of adrenal masses: a systematic review and meta-analysis. Br J Radiol. 2018;91(1086):20170520. DOI:10.1259/bjr.20170520; Ma G, Zhang X, Wang M, Xu X, Xu B, Guan Z. Role of 18F-FDG PET/CT in the diff erential diagnosis of primary benign and malignant unilateral adrenal tumors. Quant Imaging Med Surg. 2021;11(5):2013-2018. DOI:10.21037/qims20-875; Claimon A, Tantranont N, Claimon T. 18F-fl uoro-2-deoxy-Dglucose positron emission tomography/computed tomography for preoperative planning in a rare case of hyperfunctional bilateral adrenocortical carcinoma and review of literatures. World J Nucl Med. 2020;19(3):301-305. DOI:10.4103/wjnm.WJNM_86_19; Ecénarro-Montiel A, Baleato-González S, Santiago-Pérez MI, Sánchez-González J, Montesinos P, García-Figueiras R. Using the modifi ed Dixon technique to evaluate incidental adrenal lesions on 3T MRI. Radiologia (Engl Ed). 2018;60(6):485-492. DOI:10.1016/j.rx.2018.06.001; Dong A, Cui Y, Wang Y, Zuo C, Bai Y. (18)F-FDG PET/CT of adrenal lesions. AJR Am J Roentgenol. 2014;203(2):245-52. DOI:10.2214/AJR.13.11793; Leboulleux S, Dromain C, Bonniaud G, Aupérin A, Caillou B, et al. Diagnostic and prognostic value of 18-fl uorodeoxyglucose positron emission tomography in adrenocortical carcinoma: a prospective comparison with computed tomography. J Clin Endocrinol Metab. 2006;91(3):920-5. DOI:10.1210/jc.2005-1540; Ardito A, Massaglia C, Pelosi E, Zaggia B, Basile V, et al. 18F-FDG PET/CT in the post-operative monitoring of patients with adrenocortical carcinoma. Eur J Endocrinol. 2015;173(6):749-56. DOI:10.1530/EJE-15-0707; Papadakis GZ, Millo C, Stratakis CA. Benign hormonesecreting adenoma within a larger adrenocortical mass showing intensely increased activity on 18F-FDG PET/CT. Endocrine. 2016;54(1):269-270. DOI:10.1007/s12020-016-0969-7; Shimizu A, Oriuchi N, Tsushima Y, Higuchi T, Aoki J, Endo K. High [18F] 2-fl uoro-2-deoxy-D-glucose (FDG) uptake of adrenocortical adenoma showing subclinical Cushing’s syndrome. Ann Nucl Med. 2003;17(5):403-6. DOI:10.1007/BF03006609; Ansquer C, Scigliano S, Mirallié E, Taïeb D, Brunaud L, et al. 18F-FDG PET/CT in the characterization and surgical decision concerning adrenal masses: a prospective multicentre evaluation. Eur J Nucl Med Mol Imaging. 2010;37(9):1669-78. DOI:10.1007/s00259-010-1471-8; Timmers HJ, Chen CC, Carrasquillo JA, Whatley M, Ling A, et al. Staging and functional characterization of pheochromocytoma and paraganglioma by 18F-fl uorodeoxyglucose (18F-FDG) positron emission tomography. J Natl Cancer Inst. 2012;104(9):700-8. DOI:10.1093/jnci/djs188; Tiwari A, Shah N, Sarathi V, Malhotra G, Bakshi G, et al. Genetic status determines 18 F-FDG uptake in pheochromocytoma/ paraganglioma. J Med Imaging Radiat Oncol. 2017;61(6):745752. DOI:10.1111/1754-9485.12620; Kundu S, Kand P, Basu S. Comparative evaluation of iodine-131 metaiodobenzylguanidine and 18-fl uorodeoxyglucose positron emission tomography in assessing neural crest tumors: Will they play a complementary role? South Asian J Cancer. 2017;6(1):31-34. DOI:10.4103/2278-330X.202556; Kunikowska J, Matyskiel R, Toutounchi S, Grabowska-Derlatka L, Koperski L, Królicki L. What parameters from 18F-FDG PET/ CT are useful in evaluation of adrenal lesions? Eur J Nucl Med Mol Imaging. 2014;41(12):2273-80. DOI:10.1007/s00259-0142844-1; Patel D, Mehta A, Nilubol N, Dieckmann W, Pacak K, Kebebew E. Total 18F-FDG PET/CT Metabolic Tumor Volume Is Associated With Postoperative Biochemical Response in Patients With Metastatic Pheochromocytomas and Paragangliomas. Ann Surg. 2016;263(3):582-7. DOI:10.1097/SLA.0000000000001018; Nockel P, El Lakis M, Gaitanidis A, Merkel R, Patel D, et al. Preoperative 18F-FDG PET/CT in Pheochromocytomas and Paragangliomas Allows for Precision Surgery. Ann Surg. 2019;269(4):741-747. DOI:10.1097/SLA.0000000000002671; Koopman D, van Dalen JA, Stigt JA, Slump CH, Knollema S, Jager PL. Current generation time-of-fl ight (18)F-FDG PET/CT provides higher SUVs for normal adrenal glands, while maintaining an accurate characterization of benign and malignant glands. Ann Nucl Med. 2016;30(2):145-52. DOI:10.1007/s12149-015-1041-z; Chondrogiannis S, Marzola MC, Al-Nahhas A, Venkatanarayana TD, Mazza A, et al. Normal biodistribution pattern and physiologic variants of 18F-DOPA PET imaging. Nucl Med Commun. 2013;34(12):1141-9. DOI:10.1097/MNM.0000000000000008; Santhanam P, Taïeb D. Role of (18) F-FDOPA PET/ CT imaging in endocrinology. Clin Endocrinol (Oxf). 2014;81(6):789-98. DOI:10.1111/cen.12566; Noordzij W, Glaudemans AWJM, Schaafsma M, van der Horst-Schrivers ANA, Slart RHJA, et al. Adrenal tracer uptake by 18F-FDOPA PET/CT in patients with pheochromocytoma and controls. Eur J Nucl Med Mol Imaging. 2019;46(7):1560-1566. DOI:10.1007/s00259-01904332-5; Archier A, Varoquaux A, Garrigue P, Montava M, Guerin C, et al. Prospective comparison of (68)Ga-DOTATATE and (18)F-FDOPA PET/CT in patients with various pheochromocytomas and paragangliomas with emphasis on sporadic cases. Eur J Nucl Med Mol Imaging. 2016;43(7):124857. DOI:10.1007/s00259-015-3268-2; Taïeb D, Jha A, Treglia G, Pacak K. Molecular imaging and radionuclide therapy of pheochromocytoma and paraganglioma in the era of genomic characterization of disease subgroups. Endocr Relat Cancer. 2019;26(11):R627-R652. DOI:10.1530/ERC-19-0165; Nölting S, Ullrich M, Pietzsch J, Ziegler CG, Eisenhofer G, et al. Current Management of Pheochromocytoma/ Paraganglioma: A Guide for the Practicing Clinician in the Era of Precision Medicine. Cancers (Basel). 2019;11(10):1505. DOI:10.3390/cancers11101505; Taïeb D, Hicks RJ, Hindié E, Guillet BA, Avram A, et al. European Association of Nuclear Medicine Practice Guideline/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging. 2019;46(10):2112-2137. DOI:10.1007/s00259019-04398-1; Tepede AA, Welch J, Lee M, Mandl A, Agarwal SK, et al. 18F-FDOPA PET/CT accurately identifi es MEN1-associated pheochromocytoma. Endocrinol Diabetes Metab Case Rep. 2020;2020:19-0156. DOI:10.1530/EDM-19-0156. Epub ahead of print; Timmers HJ, Chen CC, Carrasquillo JA, Whatley M, Ling A, et al. Comparison of 18F-fl uoro-L-DOPA, 18F-fl uorodeoxyglucose, and 18F-fl uorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma. J Clin Endocrinol Metab. 2009;94(12):475767. DOI:10.1210/jc.2009-1248; Timmers HJ, Eisenhofer G, Carrasquillo JA, Chen CC, Whatley M, et al. Use of 6-[18F]-fl uorodopamine positron emission tomography (PET) as fi rst-line investigation for the diagnosis and localization of non-metastatic and metastatic phaeochromocytoma (PHEO). Clin Endocrinol (Oxf). 2009;71(1):11-7. DOI:10.1111/j.1365-2265.2008.03496.x; Timmers HJ, Carrasquillo JA, Whatley M, Eisenhofer G, Chen CC, et al. Usefulness of standardized uptake values for distinguishing adrenal glands with pheochromocytoma from normal adrenal glands by use of 6-18F-fl uorodopamine PET. J Nucl Med. 2007;48(12):1940-4. DOI:10.2967/jnumed.107.043281; Kaji P, Carrasquillo JA, Linehan WM, Chen CC, Eisenhofer G, et al. Th e role of 6-[18F]fl uorodopamine positron emission tomography in the localization of adrenal pheochromocytoma associated with von Hippel-Lindau syndrome. Eur J Endocrinol. 2007;156(4):483-7. DOI:10.1530/EJE-06-0712; Pacak K, Eisenhofer G, Ilias I. Diagnosis of pheochromocytoma with special emphasis on MEN2 syndrome. Hormones (Athens). 2009;8(2):111-6. DOI:10.14310/horm.2002.1227; Tehrani OS, Shields AF. PET imaging of proliferation with pyrimidines. J Nucl Med. 2013;54(6):903-12. DOI:10.2967/jnumed.112.112201; Chalkidou A, Landau DB, Odell EW, Cornelius VR, O’Doherty MJ, Marsden PK. Correlation between Ki-67 immunohistochemistry and 18F-fl uorothymidine uptake in patients with cancer: A systematic review and metaanalysis. Eur J Cancer. 2012;48(18):3499-513. DOI:10.1016/j.ejca.2012.05.001; Giammarile F, Billotey C, Lombard-Bohas C, Le Bars D, Bournaud C, et al. 18F-FLT and 18F-FDG positron emission tomography for the imaging of advanced well-diff erentiated gastroentero-pancreatic endocrine tumours. Nucl Med Commun. 2011;32(2):91-7. DOI:10.1097/MNM.0b013e3283412143; Nakajo M, Nakajo M, Kajiya Y, Jinguji M, Mori S, et al. High FDG and low FLT uptake in a thyroid papillary carcinoma incidentally discovered by FDG PET/CT. Clin Nucl Med. 2012;37(6):607-8. DOI:10.1097/RLU.0b013e318252d80f; Nakajo M, Nakajo M, Jinguji M, Tani A, Kajiya Y, et al. Diagnosis of metastases from postoperative diff erentiated thyroid cancer: comparison between FDG and FLT PET/CT studies. Radiology. 2013;267(3):891-901. DOI:10.1148/radiol.13121546; Blanchet EM, Taieb D, Millo C, Martucci V, Chen CC, et al. 18F-FLT PET/CT in the Evaluation of Pheochromocytomas and Paragangliomas: A Pilot Study. J Nucl Med. 2015;56(12):184954. DOI:10.2967/jnumed.115.159061; Yu M, Bozek J, Lamoy M, Guaraldi M, Silva P, et al. Evaluation of LMI1195, a novel 18F-labeled cardiac neuronal PET imaging agent, in cells and animal models. Circ Cardiovasc Imaging. 2011;4(4):435-43. DOI:10.1161/CIRCIMAGING.110.962126; Yu M, Bozek J, Lamoy M, Kagan M, Benites P, et al. LMI1195 PET imaging in evaluation of regional cardiac sympathetic denervation and its potential role in antiarrhythmic drug treatment. Eur J Nucl Med Mol Imaging. 2012;39(12):1910-9. DOI:10.1007/s00259-012-2204-y; Gaertner FC, Wiedemann T, Yousefi BH, Lee M, Repokis I, et al. Preclinical evaluation of 18F-LMI1195 for in vivo imaging of pheochromocytoma in the MENX tumor model. J Nucl Med. 2013;54(12):2111-7. DOI:10.2967/jnumed.113.119966; Rischpler C, Schlitter A, Herz M, Yousefi B, Von Werder A, Tauber R. First experience using LMI1195 PET in patients with the suspicion of pheochromocytoma or paraganglioma. Journal of Nuclear Medicine. 2018:59.; Yen RF, Wu VC, Liu KL, Cheng MF, Wu YW, et al. 131I-6betaiodomethyl-19-norcholesterol SPECT/CT for primary aldosteronism patients with inconclusive adrenal venous sampling and CT results. J Nucl Med. 2009;50(10):1631-7. DOI:10.2967/jnumed.109.064873; Chen YC, Chiu JS, Wang YF. NP-59 SPECT/CT imaging in stage 1 hypertensive and atypical primary aldosteronism: a 5-year retrospective analysis of clinicolaboratory and imaging features. Scientifi cWorldJournal. 2013;2013:317934. DOI:10.1155/2013/317934; Chen YC, Su YC, Wei CK, Chiu JS, Tseng CE, et al. Diagnostic value of I-131 NP-59 SPECT/CT scintigraphy in patients with subclinical or atypical features of primary aldosteronism. J Biomed Biotechnol. 2011;2011:209787. DOI:10.1155/2011/209787; Lee J, Ha J, Lee SK, Park HL, Kim SH, et al. Feasibility of Iodine-131 6β-Methyl-Iodo-19 Norcholesterol (NP-59) Scintigraphy to Complement Adrenal Venous Sampling in Management of Primary Aldosteronism: A Case Series. Int J Gen Med. 2021;14:673-680. DOI:10.2147/IJGM.S288774; Prado-Wohlwend S; Grupo de Trabajo de Endocrinología de la SEMNIM. Functional imaging of adrenal cortex. Rev Esp Med Nucl Imagen Mol (Engl Ed). 2020;39(6):393-404. DOI:10.1016/j.remn.2020.08.010.; Wagner RL, White PF, Kan PB, Rosenthal MH, Feldman D. Inhibition of adrenal steroidogenesis by the anesthetic etomidate. N Engl J Med. 1984;310(22):1415-21. DOI:10.1056/NEJM198405313102202; Bergström M, Bonasera TA, Lu L, Bergström E, Backlin C, et al. In vitro and in vivo primate evaluation of carbon-11etomidate and carbon-11-metomidate as potential tracers for PET imaging of the adrenal cortex and its tumors. J Nucl Med. 1998;39(6):982-9. PMID: 9627330; Khan TS, Sundin A, Juhlin C, Långström B, Bergström M, Eriksson B. 11C-metomidate PET imaging of adrenocortical cancer. Eur J Nucl Med Mol Imaging. 2003;30(3):403-10. DOI:10.1007/s00259-002-1025-9; Burton TJ, Mackenzie IS, Balan K, Koo B, Bird N, et al. Evaluation of the sensitivity and specifi city of (11)C-metomidate positron emission tomography (PET)-CT for lateralizing aldosterone secretion by Conn’s adenomas. J Clin Endocrinol Metab. 2012;97(1):100-9. DOI:10.1210/jc.2011-1537; O’Shea PM, O’Donoghue D, Bashari W, Senanayake R, Joyce MB, et al. 11 C-Metomidate PET/CT is a useful adjunct for lateralization of primary aldosteronism in routine clinical practice. Clin Endocrinol (Oxf). 2019;90(5):670-679. DOI:10.1111/cen.13942; Soinio M, Luukkonen AK, Seppänen M, Kemppainen J, Seppänen J, et al. Functional imaging with 11C-metomidate PET for subtype diagnosis in primary aldosteronism. Eur J Endocrinol. 2020;183(6):539-550. DOI:10.1530/EJE-20-0532; Hennings J, Sundin A, Hägg A, Hellman P. 11C-metomidate positron emission tomography aft er dexamethasone suppression for detection of small adrenocortical adenomas in primary aldosteronism. Langenbecks Arch Surg. 2010;395(7):963-7. DOI:10.1007/s00423-010-0681-7; Mendichovszky IA, Powlson AS, Manavaki R, Aigbirhio FI, Cheow H, et al. Targeted Molecular Imaging in Adrenal Disease-An Emerging Role for Metomidate PET-CT. Diagnostics (Basel). 2016;6(4):42. DOI:10.3390/diagnostics6040042; Powlson AS, Gurnell M, Brown MJ. Nuclear imaging in the diagnosis of primary aldosteronism. Curr Opin Endocrinol Diabetes Obes. 2015;22(3):150-6. DOI:10.1097/MED.0000000000000148; Bergström M, Juhlin C, Bonasera TA, Sundin A, Rastad J,et al. PET imaging of adrenal cortical tumors with the 11beta-hydroxylase tracer 11C-metomidate. J Nucl Med. 2000;41(2):275-82. PMID: 10688111; Minn H, Salonen A, Friberg J, Roivainen A, Viljanen T, et al. Imaging of adrenal incidentalomas with PET using (11) C-metomidate and (18)F-FDG. J Nucl Med. 2004;45(6):972-9. PMID: 15181132; Zolle IM, Berger ML, Hammerschmidt F, Hahner S, Schirbel A, Peric-Simov B. New selective inhibitors of steroid 11betahydroxylation in the adrenal cortex. Synthesis and structureactivity relationship of potent etomidate analogues. J Med Chem. 2008;51(7):2244-53. DOI:10.1021/jm800012w; Erlandsson M, Karimi F, Lindhe O, Långström B. (18) F-labelled metomidate analogues as adrenocortical imaging agents. Nucl Med Biol. 2009;36(4):435-45. DOI:10.1016/j.nucmedbio.2009.01.014; Bongarzone S, Basagni F, Sementa T, Singh N, Gakpetor C, et al. Development of [18F]FAMTO: A novel fl uorine-18 labelled positron emission tomography (PET) radiotracer for imaging CYP11B1 and CYP11B2 enzymes in adrenal glands. Nucl Med Biol. 2019;68-69:14-21. DOI:10.1016/j.nucmedbio.2018.11.002; Hahner S, Kreissl MC, Fassnacht M, Haenscheid H, Bock S, et al. Functional characterization of adrenal lesions using [123I] IMTO-SPECT/CT. J Clin Endocrinol Metab. 2013;98(4):150818. DOI:10.1210/jc.2012-3045; Sander K, Gendron T, Cybulska KA, Sirindil F, Zhou J, et al. Development of [18F]AldoView as the First Highly Selective Aldosterone Synthase PET Tracer for Imaging of Primary Hyperaldosteronism. J Med Chem. 2021;64(13):93219329. DOI:10.1021/acs.jmedchem.1c00539; Heinze B, Fuss CT, Mulatero P, Beuschlein F, Reincke M, et al. Targeting CXCR4 (CXC Chemokine Receptor Type 4) for Molecular Imaging of Aldosterone-Producing Adenoma. Hypertension. 2018;71(2):317-325. DOI:10.1161/HYPERTENSIONAHA.117.09975; Walenkamp AME, Lapa C, Herrmann K, Wester HJ. CXCR4 Ligands: Th e Next Big Hit? J Nucl Med. 2017;58(Suppl 2):77S-82S. DOI:10.2967/jnumed.116.186874; Ding J, Zhang Y, Wen J, Zhang H, Wang H, et al. Imaging CXCR4 expression in patients with suspected primary hyperaldosteronism. Eur J Nucl Med Mol Imaging. 2020;47(11):2656-2665. DOI:10.1007/s00259-020-04722-0; Cui Y, Zhang Y, Ding J, Wang H, Ma X, et al. A Rare AldosteroneProducing Adenoma Detected by 68Ga-pentixafor PETCT: A Case Report and Literature Review. Front Endocrinol (Lausanne). 2019;10:810. DOI:10.3389/fendo.2019.00810; https://www.medicalherald.ru/jour/article/view/1498
-
12Academic Journal
Συγγραφείς: O. M. Symonov, B. A. Kondratiuk, O. M. Gulko, A. V. Skums
Πηγή: Клінічна хірургія, Vol 85, Iss 9, Pp 35-38 (2018)
Θεματικοί όροι: 03 medical and health sciences, 0302 clinical medicine, RD1-811, феохромоцитома, лапароскопія, мультидисциплінарний підхід, адреналектомія, гемодинамічна нестабільність, Surgery
-
13Academic Journal
Συγγραφείς: V. I. Pylypchuk
Πηγή: Клінічна хірургія, Vol 85, Iss 8, Pp 68-71 (2018)
Θεματικοί όροι: об'ємні новоутворення наднирників, адреналектомія, феохромоцитома, аденома наднирника, альдостерома, 03 medical and health sciences, 0302 clinical medicine, RD1-811, Surgery
-
14Academic Journal
Πηγή: Bukovinian Medical Herald; Vol. 25 No. 4 (100) (2021); 107-111 ; Буковинский медицинский вестник; Том 25 № 4 (100) (2021); 107-111 ; Буковинський медичний вісник; Том 25 № 4 (100) (2021); 107-111 ; 2413-0737 ; 1684-7903
Θεματικοί όροι: pathogenesis arterial hypertension, Cushing's syndrome, aldosteronism, androsteroma, pheochromocytoma, патогенез, артериальная гипертензия, синдром Кушинга, альдостеронизм, андростерома, феохромоцитома, артеріальна гіпертензія, альдостеронізм
Περιγραφή αρχείου: application/pdf
-
15Academic Journal
Πηγή: Bukovinian Medical Herald; Vol. 25 No. 4 (100) (2021); 107-111
Буковинский медицинский вестник; Том 25 № 4 (100) (2021); 107-111
Буковинський медичний вісник; Том 25 № 4 (100) (2021); 107-111Θεματικοί όροι: патогенез, артериальная гипертензия, синдром Кушинга, альдостеронизм, андростерома, феохромоцитома, pathogenesis arterial hypertension, Cushing's syndrome, aldosteronism, androsteroma, pheochromocytoma, артеріальна гіпертензія, альдостеронізм, 3. Good health
Περιγραφή αρχείου: application/pdf
Σύνδεσμος πρόσβασης: http://e-bmv.bsmu.edu.ua/article/view/252785
-
16Academic Journal
Συγγραφείς: Филимонюк А.В., Смирнова Е.А., Тедорадзе Р.В., Смелкова Н.И.
Πηγή: Вестник Российского университета дружбы народов. Серия: Медицина
Θεματικοί όροι: надпочечник, диагностика, адренокортикальный рак, феохромоцитома, adrenal gland, diagnosis, adrenocortical carcinoma, pheochromocytoma
Διαθεσιμότητα: https://openrepository.ru/article?id=248395
-
17Academic Journal
Πηγή: Clinical endocrinology and endocrine surgery; № 4(56) (2016); 43-51
Клиническая эндокринология и эндокринная хирургия; № 4(56) (2016); 43-51
Клінічна ендокринологія та ендокринна хірургія; № 4(56) (2016); 43-51Θεματικοί όροι: pheochromocytoma, anesthesia, staged perioperative hemodynamic management, urapidil, refortan, феохромоцитома, анестезия, севофлуран, этапный периоперационный гемодинамический менеджмент, урапидил, рефортан, 616.452:616-089.5-031.81, анестезія, етапний периопераційний гемодинамічний менеджмент, урапідил, 6. Clean water, 3. Good health
Περιγραφή αρχείου: application/pdf
-
18Academic Journal
Πηγή: Вестник Российского университета дружбы народов. Серия: Медицина
Θεματικοί όροι: adrenal gland, надпочечник, diagnosis, adrenocortical carcinoma, диагностика, адренокортикальный рак, феохромоцитома, pheochromocytoma
Σύνδεσμος πρόσβασης: https://openrepository.ru/article?id=248395
-
19Academic Journal
Συγγραφείς: Skums, A. V., Mazur, A. P., Kondratyuk, V. A., Symonov, O. M., Gurin, P. V.
Πηγή: Clinical Endocrinology and Endocrine Surgery; No. 3 (2019); 26-33 ; Clinical Endocrinology and Endocrine Surgery; № 3 (2019); 26-33 ; 2519-2582 ; 1818-1384
Θεματικοί όροι: феохромоцитома, лапароскопічна адреналектомія, рентгенедоваскулярна селективна електрокоагуляційна оклюзія, нестабільність гемодинаміки, 616.45-002-006-089.12, лапароскопическая адреналэктомия, рентгенэдоваскулярная селективная электрокоагуляционная окклюзия, нестабильность гемодинамики, pheochromocytoma, laparoscopy, endovascular electrocoagulation occlusion of the adrenal vessels under x-ray control, adrenalectomy, hemodynamic instability
Περιγραφή αρχείου: application/pdf
Relation: http://jcees.endocenter.kiev.ua/article/view/180284/180208; http://jcees.endocenter.kiev.ua/article/view/180284
-
20Academic Journal
Συγγραφείς: I. I. Larina, N. M. Platonova, E. A. Troshina, A. A. Roslyakova, D. G. Belzevich, L. S. Selivanova, M. Yu. Ukina, L. V. Nikankina, N. M. Malysheva, A. N. Tyulpakov, L. D. Kovalevich, И. И. Ларина, Н. М. Платонова, Е. А. Трошина, А. А. Рослякова, Д. Г. Бельцевич, Л. С. Селиванова, М. Ю. Юкина, Л. В. Никанкина, Н. М. Малышева, А. Н. Тюльпаков, Л. Д. Ковалевич
Πηγή: The Russian Archives of Internal Medicine; Том 9, № 3 (2019); 165-171 ; Архивъ внутренней медицины; Том 9, № 3 (2019); 165-171 ; 2411-6564 ; 2226-6704 ; 10.20514/2226-6704-2019-9-3
Θεματικοί όροι: VHL, Von Hippel-Lindau syndrome, pheochromocytoma, hemangioblastoma, синдром фон Гиппеля-Линдау, феохромоцитома, гемангиобластома
Περιγραφή αρχείου: application/pdf
Relation: https://www.medarhive.ru/jour/article/view/924/790; https://www.medarhive.ru/jour/article/view/924/801; Wang Y., Liang G., Tian J., et al. Pedigree analysis, diagnosis and treatment in Von Hippel-Lindau syndrome: A report of three cases. Oncology Letters. 2018; 15(4): 4882-4890. doi:10.3892/ol.2018.7957.; Ершова Е.В., Юкина М.Ю., Трошина Е.А., и др. Синдром фон Хиппеля-Линдау. Ожирение и метаболизм. 2011; 2(8): 65-68. doi:10.14341/2071-8713-4955.; Varshney N., Kebede A.A., Owusu-Dapaah H., et al. A Review of Von Hippel-Lindau Syndrome. J Kidney Cancer VHL. 2017; 4(3): 20–29. doi:10.15586/jkcvhl.2017.88.; Сафронова Ю.В., Глухов Д.В., Струкова С.С., и др. Болезнь фон Хиппеля — Линдау. Поволжский онкологический вестник. 2016; 4(26): 72-75.; Юкина М.Ю., Трошина Е.А., Бельцевич Д.Г., и др. Феохромоцитома/параганглиома: клинико-генетические аспекты. Проблемы эндокринологии. 2013; 3(59):19-26. doi:10.14341/probl201359319-26.; Chittiboina P., Lonser R.R. Von Hippel-Lindau disease. Handbook of clinical neurology. 2015; 132: 139-56. doi:10.1016/B978-0-44462702-5.00010-X.; Vortmeyer A.O., Alomari A.K. Pathology of the Nervous System in Von Hippel-Lindau Disease. Journal of kidney cancer and VHL. 2015; 2(3): 114-129. doi:10.15586/jkcvhl.2015.35.; Lonser R.R., Butman J.A., Huntoon K., et al. Prospective natural history study of central nervous system hemangioblastomas in von HippelLindau disease. Journal of neurosurgery. 2014; 5(120): 1055-62. doi:10.3171/2014.1.JNS131431.; Crespigio J., Berbel L.C. L., Dias M.A., et al. Von Hippel-Lindau disease: a single gene, several hereditary tumors. Journal of endocrinological investigation. 2018; 41(1): 21-31. doi:10.1007/s40618-017-0683-1.; Girmens J.F., Erginay A., Massin P., et al. Treatment of von Hippel— Lindau retinal hemangioblastoma by the vascular endothelial growth factor receptor inhibitor SU5416 is more effective for associated macular edema than for hemangioblastomas. American Journal of Ophthalmology. 2003; 136(1): 194—196. doi:10.1016/S00029394(03)00101-6; Chretien Y., Chauveau D., Richard S., et al. Treatment of von Hippel— Lindau disease with renal involvement. Progre s en urologie: journal de l’Association franc aise d’urologie et de la Socie te franc aise d’urologie. 1997; 7: 939—947. doi:10.1053/gast.2000.18143.; Maher E.R., Neumann H.P., Richard S. Von Hippel-Lindau disease: a clinical and scientific review. European Journal of Human Genetics. 2011; 19(6): 617-23. doi:10.1038/ejhg.2010.175.; Krauss T, Ferrara AM, Links TP et al. Preventive medicine for von Hippel-Lindau disease-associated pancreatic neuroendocrine tumors. Endocr Relat Cancer. 25(9): ERC-18-0100 2018. doi:10.1530/ERC-18-0100.; Blansfield J.A., Choyke L., Morita S.Y., et al. Clinical, genetic and radiographic analysis of 108 patients with von Hippel-Lindau disease (VHL) manifested by pancreatic neuroendocrine neoplasms (PNETs). Surgery. 2007; 142: 814–818. doi:10.1016/j.surg.2007.09.012.; Yaghobi J.A., Azadeh P. Von Hippel-Lindau Disease With MultiOrgan Involvement: A Case Report and 8-Year Clinical Course With Follow-Up. The American journal of case reports. 2017; 18: 1220-1224. doi:10.12659/AJCR.907356.; Ward TL, Zarrin-Khameh N. Papillary Cystadenoma: An Incidental Finding in Tubal Ligation. Case Rep Obstet Gynecol. 2018; 2018: 7964238. 2018 Apr 23. doi:10.1155/2018/7964238; Choyke P.L., Glenn G.M., Walther M.M., et al. von Hippel—Lindau disease: Genetic, clinical, and imaging features. Radiology 1995; 194: 629—642. doi:10.1148/radiology.194.3.7862955; Simpson J.L., Carson S.A., Cisneros P. Preimplantation genetic diagnosis (PGD) for heritable neoplasia. Journal of the National Cancer Institute. Monographs. 2005; 34: 87–90. doi:10.1093/jncimonographs/lgi027.; Grossman A., Johannsson G., Quinkler M., et al. Therapy of endocrine disease: Perspectives on the management of adrenal insufficiency: clinical insights from across Europe. European journal of endocrinology. 2013;169(6): R165-75. doi:10.1530/EJE-13-0450; https://www.medarhive.ru/jour/article/view/924